Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Real-world safety profile of lecanemab: A disproportionality analysis of adverse events in the FDA adverse event reporting system. Local targets link to admitted publications; unresolved targets remain external evidence.
Current and evolving treatment strategies for the Alzheimer disease continuum
2020 · External reference
Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease
10.1016/j.arr.2021.101339 · 2021 · External reference
Lecanemab in early Alzheimer’s disease
10.1056/nejmoa2212948 · 2023 · External reference
Amyloid related imaging abnormalities (ARIA) in Amyloid Modifying Therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup
10.1016/j.jalz.2011.05.2351 · 2011 · External reference
Lecanemab, Aducanumab, and gantenerumab - Binding profiles to different forms of Amyloid-Beta might explain efficacy and side effects in clinical trials for Alzheimer’s disease
10.1007/s13311-022-01308-6 · 2023 · External reference
Serious adverse drug events reported to the FDA: analysis of the FDA Adverse Event Reporting System 2006–2014 Database
2018 · External reference
FDA grants accelerated approval for Alzheimer’s disease treatment
2023 · External reference
OpenVigil FDA–inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications
10.1371/journal.pone.0157753 · 2016 · External reference
Two randomized phase 3 studies of Aducanumab in early Alzheimer’s disease
10.14283/jpad.2022.30 · 2022 · External reference
Guideline Watch (October 2014): practice guideline for the treatment of patients with Alzheimer’s disease and other dementias
2017 · External reference
